selected publications

• article

  • Relative bioavailability of isoniazid in a fixed-Dose combination product in healthy Mexican subjects.  International Journal of Tuberculosis and Lung Disease.  18:49-54. 2014-01-01
  • Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.  Journal of Clinical Pharmacy and Therapeutics.  38:56-61. 2013-01-01
  • Effect of fluoride exposure on different immune parameters in humans.  Immunopharmacology and Immunotoxicology.  33:169-177. 2011-01-01
  • Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.  International Journal of Tuberculosis and Lung Disease.  14:1454-1460. 2010-01-01
  • Treating severe systemic lupus erythematosus with rituximab. An open study.  Reumatologia Clinica.  5:147-152. 2009-01-01
  • Simultaneous HPLC determination of isoniazid and acetylisoniazid in plasma.  Acta Chromatographica.  110-118. 2007-01-01
  • Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study.  Arthritis Research and Therapy.  8:-. 2006-01-01
  • In vivo effect of Rituximab on regulatory T cells and apoptosis in patients with rheumatoid arthritis.  Inmunologia.  25:167-172. 2006-01-01
  • Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis.  Clinical and Experimental Immunology.  141:372-380. 2005-01-01